Prof. Miklos Pless
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.
11.07.2023Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
11.07.2023ESMO Open 2023; 8:101595
König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.
Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold D, Putora P, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A, Schaer C, Biaggi C, Gillessen S, Cathomas R. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23:1441-1450.
10.10.2022Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.
10.10.2022Lancet Oncol 2022; 23:1441-1450
Papachristofilou Alexandros, Bedke Jens, Hayoz Stefanie, Schratzenstaller Ulrich, Pless Miklos, Hentrich Marcus, Krege Susanne, Lorch Anja, Aebersold Daniel-M, Putora Paul Martin, Berthold Dominik-R, Zihler Deborah, Zengerling Friedemann, Dieing Annette, Mueller Arndt-Christian, Schaer Corinne, Biaggi Christine, Gillessen Silke, Cathomas Richard
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14
27.04.2022Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
27.04.2022Cancers (Basel) 2022; 14
Jörger Markus, Metaxas Yannis, Zaman Khalil, Michielin Olivier, Mach Nicolas, Bettini Adrienne, Schmitt Andreas M, Cantoni Nathan, Caspar Clemens B, Stettler Sonja, Malval Roma, Pless Miklos, Britschgi Christian, Renner Christoph, Koeberle Dieter, Schulz Jessica D, Kopp Christoph, Hayoz Stefanie, Stathis Anastasios, von Moos Roger, Swiss Group for Clinical Cancer Research (SAKK)
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5.
18.04.2022Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
18.04.2022J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5
Furrer Katarzyna, Weder Walter, Eboulet Eric Innocents, Betticher Daniel, Pless Miklos, Stupp Roger, Krueger Thorsten, Perentes Jean Yannis, Schmid Ralph A, Lardinois Didier, Furrer Markus, Früh Martin, Peters Solange, Curioni-Fontecedro Alessandra, Stahel Rolf A, Rothschild Sacha I, Hayoz Stefanie, Opitz Isabelle
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
12.07.2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
12.07.2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020
01.11.2020SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
01.11.2020Cancer Immunol Immunother 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
Choice of first line systemic treatment in pancreatic cancer among national experts
Glatzer M, Pless M, Pederiva S, Pestalozzi B, Berger M, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora P. Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology 2020; 20 (2020):686-690.
31.03.2020Choice of first line systemic treatment in pancreatic cancer among national experts
31.03.2020Pancreatology 2020; 20 (2020):686-690
Glatzer Markus, Pless Miklos, Pederiva S., Pestalozzi Bernhard, Berger M.D., Inauen Roman, Winterhalder Ralf, Montemurro Michael, Horber Daniel, Putora Paul Martin
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina-Vila M, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Palmero R, Massutí B, Stahel R, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 2019; 15:416-425.
05.12.2019Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
05.12.2019J Thorac Oncol 2019; 15:416-425
Molina-Vila Miguel-Angel, Ponce Aix Santiago, Carcereny Enric, Früh Martin, Pless Miklos, Popat Sanjay, Cuffe Sinead, Bidoli Paolo, Kammler Roswitha, Roschitzki-Voser Heidi, Tsourti Zoi, Karachaliou Niki, Palmero Ramon, Massutí Bartomeu, Stahel Rolf A, Dafni Urania, Jordana-Ariza Núria, Balada-Bel Ariadna, Garzón-Ibáñez Mónica, García-Peláez Beatriz, Mayo-de-Las-Casas Clara, Felip Enriqueta, Curioni Fontecedro Alessandra, Gautschi Oliver, Peters Solange, Rosell Rafael
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Papachristofilou A, Kallen K, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H, Koch S, Gnad-Vogt U, Griesinger F, Geißler M, Bischoff H, Hipp M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019; 7:38.
08.02.2019Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
08.02.2019J Immunother Cancer 2019; 7:38
Papachristofilou Alexandros, Kallen Karl-Josef, Fotin-Mleczek Mariola, Schröder Andreas, Scheel Birgit, Muth Anke, Seibel Tobias, Stosnach Claudia, Doener Fatma, Hong Henoch S, Koch Sven D, Gnad-Vogt Ulrike, Griesinger Frank, Geißler Michael, Bischoff Helge, Hipp Madeleine M, Klinkhardt Ute, Früh Martin, Sebastian Martin, Weiss Christian, Pless Miklos, Cathomas Richard, Hilbe Wolfgang, Pall Georg, Wehler Thomas, Alt Jürgen, Zippelius Alfred
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
26.09.2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
26.09.2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrausch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018
21.08.2018Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
21.08.2018J Thorac Oncol 2018
Metaxas Yannis, Froesch Patrizia, Löffler-Baumann Melanie, Pratsch-Peter Susanne, Russell Prudence, Mingrone Walter, Savic Spasenija, Thapa Bibhusal, Früh Martin, Pless Miklos, von Moos Roger, Mauti Laetitia, O'Byrne Kenneth, Petrausch Ulf, Wolleb Sybille, Rivalland Gareth, Klingbiel Dirk, Kao Steven, Schmid Sabine, Nowak Anna K, Gautschi Oliver, Bartnick Tammo, Hughes Brett G, Bouchaab Hasna, Rothschild Sacha, Pavlakis Nick, John Thomas
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
Balmelli C, Stenner F, Pless M, Weidner S, Zimmermann S, Güthner C, Cristina V, Cathomas R, Feuerlein K, Siano M, Railic N, Rothschild S. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. J Cancer 2018; 9:250-255.
01.01.2018Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
01.01.2018J Cancer 2018; 9:250-255
Balmelli Catharina, Stenner Frank, Pless Miklos, Weidner Sabine, Zimmermann Stefan, Güthner Christiane, Cristina Valerie, Cathomas Richard, Feuerlein Kristin, Siano Marco, Railic Nikola, Rothschild Sacha I
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
10.04.2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
10.04.2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
23.11.2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
23.11.2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
11.08.2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
11.08.2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
06.07.2015Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
06.07.2015J Clin Oncol 2015; 33:2523-9
Mamot Christoph, Zucca Emanuele, Dirnhofer Stephan, Rusterholz Corinne, Biaggi Christine, Samarin Andrei, Hany Thomas, Gigli Federica, Krasniqi Fatime, Bargetzi Mario, Pless Miklos, Mey Ulrich, Driessen Christoph, Pabst Thomas, Renner Christoph, Hitz Felicitas, Klingbiel Dirk, Martinelli Giovanni
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
05.03.2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
05.03.2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
10.09.2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
10.09.2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Multidisciplinary care in patients with prostate cancer: room for improvement
Strebel R, Winterhalder R, Morant R, Pless M, Huber U, Fehr M, Gillessen Sommer S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.
26.03.2013Multidisciplinary care in patients with prostate cancer: room for improvement
26.03.2013Support Care Cancer 2013; 21:2327-33
Strebel Räto T, Winterhalder Ralph, Morant Rudolf, Pless Miklos, Huber Urs, Fehr Martin, Gillessen Sommer Silke, Schmid Hans-Peter, Sulser Tullio, Cathomas Richard
Analysis of the EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma before Treatment with Gefitinib
Bontognali S, Pless M, Brutsche M, Fischer C, Rochlitz C, Buess M. Analysis of the EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma before Treatment with Gefitinib. Onkologie 2013; 36:161-6.
18.03.2013Analysis of the EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma before Treatment with Gefitinib
18.03.2013Onkologie 2013; 36:161-6
Bontognali Sven, Pless Miklos, Brutsche Martin, Fischer Claude, Rochlitz Christoph, Buess Martin